Recommendations for Validation of LC-MS/MS Bioanalytical Methods for Protein Biotherapeutics
Journal Title: The AAPS Journal - Year 2015, Vol 17, Issue 1
Abstract
This paper represents the consensus views of a cross-section of companies and organizations from the USA and Canada regarding the validation and application of liquid chromatography tandem mass spectrometry (LC-MS/MS) methods for bioanalysis of protein biotherapeutics in regulated studies. It was prepared under the auspices of the AAPS Bioanalytical Focus Group’s Protein LC-MS Bioanalysis Subteam and is intended to serve as a guide to drive harmonization of best practices within the bioanalytical community and provide regulators with an overview of current industry thinking on applying LC-MS/MS technology for protein bioanalysis. For simplicity, the scope was limited to the most common current approach in which the protein is indirectly quantified using LC-MS/MS measurement of one or more of its surrogate peptide(s) produced by proteolytic digestion. Within this context, we considered a range of sample preparation approaches from simple in-matrix protein denaturation and digestion to complex procedures involving affinity capture enrichment. Consideration was given to the method validation experiments normally associated with traditional LC-MS/MS and ligand-binding assays. Our collective experience, thus far, is that LC-MS/MS methods for protein bioanalysis require different development and validation considerations than those used for small molecules. The method development and validation plans need to be tailored to the particular assay format being established, taking into account a number of important factors: the intended use of the assay, the test species or study population, the characteristics of the protein biotherapeutic and its similarity to endogenous proteins, potential interferences, as well as the nature, quality, and availability of reference and internal standard materials.
Authors and Affiliations
Rand Jenkins, Jeffrey X. Duggan, Anne-Françoise Aubry, Jianing Zeng, Jean W. Lee, Laura Cojocaru, Dawn Dufield, Fabio Garofolo, Surinder Kaur, Gary A. Schultz, Keyang Xu, Ziping Yang, John Yu, Yan J. Zhang, Faye Vazvaei
Keywords
Related Articles
- EP ID EP680888
- DOI 10.1208/s12248-014-9685-5
- Views 58
- Downloads 0
Carrier-based strategies for targeting protein and peptide drugs to the lungs
With greater interest in delivery of protein and peptide-based drugs to the lungs for topical and systemic activity, a range of new devices and formulations are being investigated. While a great deal of recent research h...
Points to Consider when Establishing Drug Product Specifications for Parenteral Microspheres
Drug product specifications are a critical element of a good control strategy. Parenteral microsphere products are complex dosage forms, requiring careful development of test methods and acceptance criteria for the speci...
Screening for Potential Adjuvants Administered by the Pulmonary Route for Tuberculosis Vaccines
Tuberculosis (TB) infects one third of the world’s population, and new infections occur at a rate of 1/s. Better vaccines are needed than the live mycobacterium Bacille Calmette-Guérin (BCG). Alveolar mac...
Key elements of bioanalytical method validation for macromolecules
The Third American Association of Pharmaceutical Scientists/US Food and Drug Administration (FDA) Bioanalytical Workshop, which was held May 1 and 2, 2006, in Arlington, VA, addressed bioanalytical assays that are being...
Preparation and characterization of gelatin surface modified PLGA microspheres
This study optimized conditions for preparing and characterizing gelatin surface modified poly (lactic-co-glycolic acid) (PLGA) copolymer microspheres and determined this systems interaction with fibronectin. Some gelati...